Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18385163 | 1.00 | PTGER4 (0.32) | PTGER4KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18385139 | 0.99 | PTGER4 (0.31) | PTGER4KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18385129 | 0.99 | PTGER4 (0.31) | PTGER4KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18385151 | 0.99 | PTGER4 (0.31) | PTGER4KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18385143 | 0.99 | PTGER4 (0.31) | PTGER4KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18385157 | 0.99 | PTGER4 (0.31) | PTGER4KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18385141 | 0.99 | PTGER4 (0.31) | PTGER4KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL18385620 | 0.98 | PTGER4 (0.32) | PTGER4KDM4EATML3MBTL1 | |
| SCHEMBL18385604 | 0.98 | PTGER4 (0.32) | PTGER4KDM4EATML3MBTL1 | |
| SCHEMBL18385595 | 0.97 | PTGER4 (0.31) | PTGER4KDM4EMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170018719-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170018719-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170018719-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | CD99, BMI1, ETV6 | PTGER4 2521/4885KDM4E 255/4885MEN1 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.